Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
|Articles|July 30, 2007
OmniComm Systems, Inc. Responds to Industry's Growing Demand for Integrated Electronic Data Capture (EDC) Solutions and Signs 15 New Deals in Second Quarter 2007
OmniComm Systems, Inc. Responds to Industry's Growing Demand for Integrated Electronic Data Capture (EDC) Solutions and Signs 15 New Deals in Second Quarter 2007
Advertisement
FT. LAUDERDALE, FL, July 23, 2007-/MarketWire/-OmniComm Systems, Inc. (OTC Bulletin Board: OMCM.OB), a leader in integrated electronic data capture (EDC) solutions for clinical trials, today announced that they have closed 15 new business deals in Q2, 2007. Key market segments for the new business include pharmaceutical, medical device, contract research organizations (CRO) and academic medical center customers, including a high profile Top 50 pharmaceutical company. TrialMaster will be implemented in both an ASP, fully hosted environment for the new trials and also in 2 new Technology Transfer deployments for those clients that want to bring EDC in-house.
OmniComm’s Sr. Vice President of Business Development, Stephen Johnson, commented, “The company’s escalating growth is a direct result of the drug development industry’s need for flexible and integrated solutions for clinical trials. TrialMaster provides sponsors with a feature rich EDC product that is easy to use, easy to integrate with and is not laden with hidden or exorbitant costs.” Added Johnson, “Our Support and Consulting Services groups are made up of industry veterans that stand ready to deliver quality driven solutions and support for our customers using EDC.”
Advertisement
Related to this article
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where AI Governance in Clinical Development Falls Short
2
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
3
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
4
Clinical Trials Do Not Have a Data Problem, They Have a Decision-Readiness Problem
5